WO2004011632A3 - Oligodendrocyte production from multipotent neural stem cells - Google Patents

Oligodendrocyte production from multipotent neural stem cells Download PDF

Info

Publication number
WO2004011632A3
WO2004011632A3 PCT/CA2003/001151 CA0301151W WO2004011632A3 WO 2004011632 A3 WO2004011632 A3 WO 2004011632A3 CA 0301151 W CA0301151 W CA 0301151W WO 2004011632 A3 WO2004011632 A3 WO 2004011632A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
neural stem
multipotent neural
oligodendrocyte
oligodendrocyte production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001151
Other languages
French (fr)
Other versions
WO2004011632A2 (en
Inventor
Samuel Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cell Therapeutics Inc
Original Assignee
Stem Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Therapeutics Inc filed Critical Stem Cell Therapeutics Inc
Priority to CA002492542A priority Critical patent/CA2492542A1/en
Priority to JP2004523706A priority patent/JP4783013B2/en
Priority to AU2003250697A priority patent/AU2003250697B2/en
Priority to EP03771036A priority patent/EP1549740A2/en
Priority to US10/523,253 priority patent/US7704737B2/en
Publication of WO2004011632A2 publication Critical patent/WO2004011632A2/en
Publication of WO2004011632A3 publication Critical patent/WO2004011632A3/en
Anticipated expiration legal-status Critical
Priority to AU2008203234A priority patent/AU2008203234A1/en
Priority to US12/698,757 priority patent/US20100135968A1/en
Priority to US13/424,065 priority patent/US20120189575A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.
PCT/CA2003/001151 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells Ceased WO2004011632A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002492542A CA2492542A1 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
JP2004523706A JP4783013B2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from pluripotent neural stem cells
AU2003250697A AU2003250697B2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
EP03771036A EP1549740A2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
US10/523,253 US7704737B2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
AU2008203234A AU2008203234A1 (en) 2002-07-30 2008-07-21 Oligodendrocyte production from multipotent neural stem cells
US12/698,757 US20100135968A1 (en) 2002-07-30 2010-02-02 Oligodendrocyte Production From Multipotent Neural Stem Cells
US13/424,065 US20120189575A1 (en) 2002-07-30 2012-03-19 Oligodendrocyte Production from Multipotent Neural Stem Cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39919202P 2002-07-30 2002-07-30
US60/399,192 2002-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/698,757 Division US20100135968A1 (en) 2002-07-30 2010-02-02 Oligodendrocyte Production From Multipotent Neural Stem Cells

Publications (2)

Publication Number Publication Date
WO2004011632A2 WO2004011632A2 (en) 2004-02-05
WO2004011632A3 true WO2004011632A3 (en) 2004-04-15

Family

ID=31188551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001151 Ceased WO2004011632A2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells

Country Status (6)

Country Link
US (3) US7704737B2 (en)
EP (2) EP2095823A1 (en)
JP (1) JP4783013B2 (en)
AU (2) AU2003250697B2 (en)
CA (1) CA2492542A1 (en)
WO (1) WO2004011632A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846898B2 (en) 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
EP1489163A4 (en) * 2002-03-27 2007-08-08 Inst Of Gene And Brain Science Method of inducing growth of nerve stem cells
WO2004035086A2 (en) * 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2007036033A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
US9795652B2 (en) * 2010-02-25 2017-10-24 University Of South Florida Use of endogenous antioxidant proteins in the treatment of stroke
WO2018093681A1 (en) * 2016-11-15 2018-05-24 Neuralstem, Inc. Multipotent neural stem cells that express platelet derived growth factor (pdgf) receptor and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010292A1 (en) * 1992-10-28 1994-05-11 Neurospheres Ltd. Biological factors and neural stem cells
WO1996015226A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397834B1 (en) * 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
US5506117A (en) 1989-10-18 1996-04-09 Cytokinetics, Inc. Biochemical process for growing living cells by measuring the amount of nutrient added to the reaction medium
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
EP0467279A3 (en) 1990-07-18 1992-08-05 Takeda Chemical Industries, Ltd. Polypeptides having c-amp producing activity
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
WO1993003757A1 (en) * 1991-08-16 1993-03-04 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5623050A (en) 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
WO1994009119A1 (en) * 1992-10-16 1994-04-28 Neurospheres Ltd. Remyelination using neural stem cells
CN1141058A (en) * 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 In situ modification and manipulation of stem cells of the central nervous system
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US20020136705A1 (en) 1998-06-30 2002-09-26 Jonathan Dinsmore Porcine spinal cord cells and their use in spinal cord repair
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
DE19917505A1 (en) * 1999-04-17 2000-10-19 Dresden Arzneimittel Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
EP1185552A1 (en) * 1999-06-16 2002-03-13 Myelos Corporation Retro-inverso peptides derived from interleukin-3
US7160724B2 (en) 2000-03-09 2007-01-09 University Of South Florida Human cord blood as a source of neural tissue for repair of the brain and spinal cord
JP2004511266A (en) * 2000-04-12 2004-04-15 チルドレンズ　ホスピタル　オブ　フィラデルフィア Therapeutic uses for mesenchymal stromal cells
US6673606B1 (en) * 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
DE10033219A1 (en) 2000-07-07 2002-01-24 Univ Heidelberg Use of granulocyte colony stimulating factor as neuroprotective agent, for treating acute ischemia and neurodegenerative diseases
MXPA03002045A (en) * 2000-09-08 2003-07-24 Amgen Inc G-csf analog compositions and methods.
DE60220894T2 (en) * 2001-03-12 2008-02-28 Institute Of Gene And Brain Science USE OF INTERLEUKIN-12 FOR THE TREATMENT OF NERVE DAMAGE
US20020198150A1 (en) * 2001-06-07 2002-12-26 Ayelet Chajut Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
WO2004035086A2 (en) 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20080286234A1 (en) * 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010292A1 (en) * 1992-10-28 1994-05-11 Neurospheres Ltd. Biological factors and neural stem cells
WO1996015226A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, DUBOIS T M ET AL: "GRANULOCYTE MACROPHAGE - COLONY STIMULATING FACTOR ( GM - CSF ) IS A FATE DETERMINATION AND DIFFERENTIATION FACTOR FOR NEURAL STEM CELL - GENERATED OLIGODENDROCYTE PRECURSORS ( OLPS ).", XP002267009, Database accession no. PREV200300293880 *
GAGE F H: "Mammalian neural stem cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, no. 5457, 25 February 2000 (2000-02-25), pages 1433 - 1438, XP002220467, ISSN: 0036-8075 *
KOHAMA I ET AL: "Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord.", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE. 1 FEB 2001, vol. 21, no. 3, 1 February 2001 (2001-02-01), pages 944 - 950, XP002267008, ISSN: 1529-2401 *
MCQUALTER J L ET AL: "Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.", THE JOURNAL OF EXPERIMENTAL MEDICINE. 1 OCT 2001, vol. 194, no. 7, 1 October 2001 (2001-10-01), pages 873 - 881, XP002267007, ISSN: 0022-1007 *
MEHLER M F ET AL: "Cytokines regulate the cellular phenotype of developing neural lineage species.", INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR DEVELOPMENTAL NEUROSCIENCE. 1995 JUN-JUL, vol. 13, no. 3-4, June 1995 (1995-06-01), pages 213 - 240, XP002267006, ISSN: 0736-5748 *
See also references of EP1549740A2 *
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 329.12 URL - http://sf *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846898B2 (en) 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
US8435949B2 (en) 2004-02-13 2013-05-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis

Also Published As

Publication number Publication date
EP2095823A1 (en) 2009-09-02
WO2004011632A2 (en) 2004-02-05
US7704737B2 (en) 2010-04-27
CA2492542A1 (en) 2004-02-05
EP1549740A2 (en) 2005-07-06
JP4783013B2 (en) 2011-09-28
US20120189575A1 (en) 2012-07-26
AU2003250697B2 (en) 2008-05-01
AU2003250697A1 (en) 2004-02-16
AU2008203234A1 (en) 2008-08-07
JP2005534302A (en) 2005-11-17
US20050244965A1 (en) 2005-11-03
US20100135968A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
WO2006018220A8 (en) Method for the production of dihydropteridinones
WO2005003320A3 (en) Neuronal differentiation of stem cells
WO2005063971A3 (en) Definitive endoderm
WO2005030240A3 (en) Vege-cor vege-d materials and methods for stimulation of neural stem cells
WO2007022529A3 (en) Method of treating inflammatory diseases
WO2003054189A3 (en) Methods for the transformation of vegetal plastids
WO2003051362A3 (en) Polymorphs of clopidogrel hydrogensulfate
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
WO2003018767A3 (en) Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
WO2004015085A3 (en) Method and compositions relating to 5’-chimeric ribonucleic acids
WO2004018694A3 (en) Method for producing ketocarotinoids in genetically modified organisms
WO2004101889A3 (en) Use of hemicellulase composition in mechanical pulp production
NO20053206L (en) Process for producing ketocarotenoids in the cultivation of genetically modified organisms.
MX2007002470A (en) Substituted phenylaminothiazoles and use thereof.
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them
WO2004011632A3 (en) Oligodendrocyte production from multipotent neural stem cells
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
WO2007006870A3 (en) Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2005001042A8 (en) Smooth muscle progenitor cells
WO2005017100A3 (en) Ribonucleases and methods of making them recombinantly
WO2004072023A3 (en) Oxathiin carboxamide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003250697

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2492542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10523253

Country of ref document: US

Ref document number: 2004523706

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003771036

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003771036

Country of ref document: EP